|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pui CH, Campana D, Pei D, Bowman WP,
Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu
M, et al: Treating childhood acute lymphoblastic leukemia without
cranial irradiation. N Engl J Med. 360:2730–2741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Den Boer ML, Harms DO, Pieters R, Kazemier
KM, Gobel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, et
al: Patient stratification based on
prednisolone-vincristine-asparaginase resistance profiles in
children with acute lymphoblastic leukemia. J Clin Oncol.
21:3262–3268. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dördelmann M, Reiter A, Borkhardt A,
Ludwig WD, Götz N, Viehmann S, Gadner H, Riehm H and Schrappe M:
Prednisone response is the strongest predictor of treatment outcome
in infant acute lymphoblastic leukemia. Blood. 94:1209–1217.
1999.PubMed/NCBI
|
|
5
|
Kaspers GJ, Veerman AJ, Pieters R, Van
Zantwijk CH, Smets LA, Van Wering ER and Van Der Does-Van Den Berg
A: In vitro cellular drug resistance and prognosis in newly
diagnosed childhood acute lymphoblastic leukemia. Blood.
90:2723–2729. 1997.PubMed/NCBI
|
|
6
|
Pieters R, Huismans DR, Loonen AH, Hählen
K, van der Does-van den Berg A, van Wering ER and Veerman AJ:
Relation of cellular drug resistance to long-term clinical outcome
in childhood acute lymphoblastic leukaemia. Lancet. 338:399–403.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zou YF, Xu JH, Wang F, Liu S, Tao JH, Cai
J, Lian L, Xiao H, Chen PL, Tian G, et al: Association study of
glucocorticoid receptor genetic polymorphisms with efficacy of
glucocorticoids in systemic lupus erythematosus: A prospective
cohort study. Autoimmunity. 46:531–536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sousa AR, Lane SJ, Cidlowski JA, Staynov
DZ and Lee TH: Glucocorticoid resistance in asthma is associated
with elevated in vivo expression of the glucocorticoid receptor
beta-isoform. J Allergy Clin Immunol. 105:943–950. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Gou X, Jiang T and Ouyang J: The
effects of microRNAs on glucocorticoid responsiveness. J Cancer Res
Clin Oncol. 143:1005–1011. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bouillet P, Huang DC, O'Reilly LA,
Puthalakath H, O'Connor L, Cory S, Adams JM and Strasser A: The
role of the pro-apoptotic Bcl-2 family member bim in physiological
cell death. Ann N Y Acad Sci. 926:83–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jing D, Bhadri VA, Beck D, Thoms JA, Yakob
NA, Wong JW, Knezevic K, Pimanda JE and Lock RB: Opposing
regulation of BIM and BCL2 controls glucocorticoid-induced
apoptosis of pediatric acute lymphoblastic leukemia cells. Blood.
125:273–283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lv M, Zhang X, Jia H, Li D, Zhang B, Zhang
H, Hong M, Jiang T, Jiang Q, Lu J, et al: An oncogenic role of
miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by
targeting glucocorticoid receptor-α and cAMP/PKA pathways.
Leukemia. 26:769–777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liang YN, Tang YL, Ke ZY, Chen YQ, Luo XQ,
Zhang H and Huang LB: miR-124 contributes to glucocorticoid
resistance in acute lymphoblastic leukemia by promoting
proliferation, inhibiting apoptosis and targeting the
glucocorticoid receptor. J Steroid Biochem Mol Biol. 172:62–68.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tessel MA, Benham AL, Krett NL, Rosen ST
and Gunaratne PH: Role for microRNAs in regulating glucocorticoid
response and resistance in multiple myeloma. Horm Cancer.
2:182–189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang X, Li C, Ju S, Wang Y, Wang H and
Zhong R: Myeloma cell adhesion to bone marrow stromal cells confers
drug resistance by microRNA-21 up-regulation. Leuk Lymphoma.
52:1991–1998. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Molitoris JK, McColl KS and Distelhorst
CW: Glucocorticoid-mediated repression of the oncogenic microRNA
cluster miR-17~92 contributes to the induction of Bim and
initiation of apoptosis. Mol Endocrinol. 25:409–420. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Harada M, Pokrovskaja-Tamm K, Söderhäll S,
Heyman M, Grander D and Corcoran M: Involvement of miR17 pathway in
glucocorticoid-induced cell death in pediatric acute lymphoblastic
leukemia. Leuk Lymphoma. 53:2041–2050. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen H, Zhang D, Zhang G, Li X, Liang Y,
Kasukurthi MV, Li S, Borchert GM and Huang J: A semantics-oriented
computational approach to investigate microRNA regulation on
glucocorticoid resistance in pediatric acute lymphoblastic
leukemia. BMC Med Inform Decis Mak. 18 (Suppl 2):S572018.
View Article : Google Scholar
|
|
21
|
Kang J, Kisenge RR, Toyoda H, Tanaka S, Bu
J, Azuma E and Komada Y: Chemical sensitization and regulation of
TRAIL-induced apoptosis in a panel of B-lymphocytic leukaemia cell
lines. Br J Haematol. 123:921–932. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Toyoda H, Ido M, Hayashi T, Gabazza EC,
Suzuki K, Kisenge RR, Kang J, Hori H and Komada Y: Experimental
treatment of human neuroblastoma using live-attenuated poliovirus.
Int J Oncol. 24:49–58. 2004.PubMed/NCBI
|
|
23
|
Bhadri VA, Trahair TN and Lock RB:
Glucocorticoid resistance in paediatric acute lymphoblastic
leukaemia. J Paediatr Child Health. 48:634–640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lauten M, Cario G, Asgedom G, Welte K and
Schrappe M: Protein expression of the glucocorticoid receptor in
childhood acute lymphoblastic leukemia. Haematologica.
88:1253–1258. 2003.PubMed/NCBI
|
|
25
|
Tissing WJ, Meijerink JP, Brinkhof B,
Broekhuis MJ, Menezes RX, den Boer ML and Pieters R:
Glucocorticoid-induced glucocorticoid-receptor expression and
promoter usage is not linked to glucocorticoid resistance in
childhood ALL. Blood. 108:1045–1049. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paugh SW, Bonten EJ, Savic D, Ramsey LB,
Thierfelder WE, Gurung P, Malireddi RK, Actis M, Mayasundari A, Min
J, et al: NALP3 inflammasome upregulation and CASP1 cleavage of the
glucocorticoid receptor cause glucocorticoid resistance in leukemia
cells. Nat Genet. 47:607–614. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Geng CD and Vedeckis WV: A new, lineage
specific, autoup-regulation mechanism for human glucocorticoid
receptor gene expression in 697 pre-B-acute lymphoblastic leukemia
cells. Mol Endocrinol. 25:44–57. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ledderose C, Möhnle P, Limbeck E, Schütz
S, Weis F, Rink J, Briegel J and Kreth S: Corticosteroid resistance
in sepsis is influenced by microRNA-124-induced downregulation of
glucocorticoid receptor-alpha. Crit Care Med. 40:2745–2753. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gasson JC, Ryden T and Bourgeois S: Role
of de novo DNA methylation in the glucocorticoid resistance of a
T-lymphoid cell line. Nature. 302:621–623. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Charmandari E, Kino T, Ichijo T, Jubiz W,
Mejia L, Zachman K and Chrousos GP: A novel point mutation in helix
11 of the ligand-binding domain of the human glucocorticoid
receptor gene causing generalized glucocorticoid resistance. J Clin
Endocrinol Metab. 92:3986–3990. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mavrakis KJ, Wolfe AL, Oricchio E,
Palomero T, de Keersmaecker K, McJunkin K, Zuber J, James T, Khan
AA, Leslie CS, et al: Genome-wide RNA-mediated interference screen
identifies miR-19 targets in Notch-induced T-cell acute
lymphoblastic leukaemia. Nat Cell Biol. 12:372–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Scherr M, Elder A, Battmer K, Barzan D,
Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor
J, et al: Differential expression of miR-17~92 identifies BCL2 as a
therapeutic target in BCR-ABL-positive B-lineage acute
lymphoblastic leukemia. Leukemia. 28:554–565. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu Z, Sharp PP, Yao Y, Segal D, Ang CH,
Khaw SL, Aubrey BJ, Gong J, Kelly GL, Herold MJ, et al: BET
inhibition represses miR17-92 to drive BIM-initiated apoptosis of
normal and transformed hematopoietic cells. Leukemia. 30:1531–1541.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kotani A, Ha D, Hsieh J, Rao PK, Schotte
D, den Boer ML, Armstrong SA and Lodish HF: miR-128b is a potent
glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia
cells and exerts cooperative effects with miR-221. Blood.
114:4169–4178. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang A, Ma J, Wu M, Qin W, Zhao B, Shi Y,
Jin Y and Xie Y: Aberrant microRNA-182 expression is associated
with glucocorticoid resistance in lymphoblastic malignancies. Leuk
Lymphoma. 53:2465–2473. 2012. View Article : Google Scholar : PubMed/NCBI
|
